Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

Journal of Translational Medicine

Jong-Baeck Lim¹  Hye Won Chung¹ 

[1] Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

关键词: Soluble CD40 ligand;    Prognostic;    Pancreatic cancer;    Diagnostic;    Biomarker;   

Others  :  814974
DOI  :  10.1186/1479-5876-12-102

 received in 2014-02-20, accepted in 2014-04-08,  发布年份 2014

【 摘 要 】

Background

CD40-CD40 ligand (CD40L) interaction is considered to contribute to the promotion of prothrombotic responses and production of angiogenesis-associated factor in addition to adaptive immune responses. Recently, the role of soluble CD40L (sCD40L) has gained interest in cancer, although its exact functions remain unknown. This study evaluated the clinical significance of sCD40L in patients with pancreatic ductal adenocarcinoma (PDAC) and validated its utility as a PDAC diagnostic and prognostic biomarker.

Methods

Serum sCD40L levels were measured by chemiluminescent immunoassay and compared among normal, chronic pancreatitis (CP, high-risk), and PDAC group in both training (n = 25 per group) and independent validation (n = 30, 30, and 55, respectively) datasets through one-way ANOVA test with the post-hoc Bonferroni method. To evaluate the diagnostic potential of serum sCD40L for PDAC, receiver operating characteristic (ROC) curves were generated and logistic regression analysis was conducted. To investigate the sCD40L-assoicated cytokines/chemokines in PDAC, cytokines/chemokines levels were analyzed by a MILLIPLEX MAP Human Cytokine/Chemokine Kit. To assess the prognostic potentials of sCD40L, Kaplan-Meier survival curve and Cox proportional-hazards regression analysis were applied.

Results

Serum sCD40L levels were significantly higher in PDAC group compared with non-cancer groups in both training (p < 0.05) and validation (p < 0.05) datasets. Clinically, serum sCD40L closely correlated with unresectability (γ_s = 0.342, p = 0.011) and distant metastasis (γ_s = 0.294, p = 0.030) of PDAC. ROC curve and logistic regression analysis demonstrated the remarkable predictive potentials of serum sCD40L for PDAC (80.0% sensitivity and 85.5% specificity at cut-off point, 0.45; logistic regression), superior to those of CA19-9 and CEA. According to cytokines/chemokines assay, serum sCD40L levels were closely correlated with serum levels of pro-angiogenic cytokines (EGF, VEGF, IL-8) and immunosuppressive cytokines (IL-6, IL-10, IL-1RA). Kaplan-Meier survival analysis demonstrated patients with high-serum sCD40L (> 35,000 ng/ml) had a poorer prognosis than those with low-serum sCD40L (log-rank, p = 0.015). Multivariate Cox regression analysis yielded a hazard ratio of 2.509 (95% CI, 1.038–6.067, p = 0.041) for mortality in the high-serum sCD40L group.

Conclusions

Serum sCD40L is correlated with immunosuppression and angiogenesis in PDAC carcinogenesis/progression, and is a promising diagnostic and prognostic biomarker for PDAC superior to CA19-9 and CEA.

【 授权许可】

   
2014 Chung and Lim; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17.
• [2]Noelle RJ: CD40 and its ligand in host defense. Immunity 1996, 4:415-419.
• [3]Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L: Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circ 1999, 100:614-620.
• [4]Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009, 229:152-172.
• [5]Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
• [6]Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G, Ambrogi V, Spila A, Palmirotta R, D’Alessandro R, Davì G, Guadagni F, Ferroni P: Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004, 10:610-614.
• [7]Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, Briscoe DM: CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol 2008, 181:8088-8095.
• [8]Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, Mukhopadhyay D, Briscoe DM: Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000, 96:3801-3808.
• [9]Danese S, Scaldaferri F, Vetrano S, Stefanelli T, Graziani C, Repici A, Ricci R, Straface G, Sgambato A, Malesci A, Fiocchi C, Rutella S: Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 2007, 56:1248-1256.
• [10]Schonbeck U, Varo N, Libby P, Buring J, Ridker PM: Soluble CD40L and cardiovascular risk in women. Circ 2001, 104:2266-2268.
• [11]Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC: CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 2003, 101:2762-2769.
• [12]Cavanaugh PG, Sloane BF, Honn KV: Role of the coagulation system in tumor cell-induced platelet aggregation and metastasis. Haemostasis 1988, 18:37-46.
• [13]Biggerstaff JP, Seth N, Amirkhosravi A, Amaya M, Fogarty S, Meyer TV, Siddiqui F, Francis JL: Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 1999, 17:723-730.
• [14]Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, Ambrogi V, Spila A, D’Alessandro R, Gazzaniga PP, Guadagni F, Ferroni P: Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemostasis 2003, 89:177-184.
• [15]Freedman JE: CD40-CD40L and platelet function: beyond hemostasis. Circ Res 2003, 92:944-946.
• [16]Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B: Platelet activation in patients with advanced gastric cancer. Neoplasma 2010, 57:145-150.
• [17]Dammacco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V: Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med 2013, 13:85-97.
• [18]Pinzon R, Drewinko B, Trujillo JM, Guinee V, Giacco G: Pancreatic carcinoma and Trousseau’s syndrome: experience at a large cancer center. J Clin Oncol 1986, 4:509-514.
• [19]Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB: CD40 expression on human lung cancer correlates with metastatic spread. Canc Immunol Immunother 2000, 49:101-108.
• [20]Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J: Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 2012, 120:3030-3038.
• [21]Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M: Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 1998, 100:135-141.
• [22]Caggiari L, Guidoboni M, Vaccher E, Barzan L, Franchin G, Gloghini A, Martorelli D, Zancai P, Bortolin MT, Mazzucato M, Serraino D, Carbone A, De Paoli P, Dolcetti R: High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. Infect Agent Canc 2007, 2:5-15. BioMed Central Full Text
• [23]Li D, Xie K, Wolff R, Abbruzzese J: Pancreatic cancer. Lancet 2004, 363:1049-1057.
• [24]Klein D, Timoneri F, Ichii H, Ricordi C, Pastori RL: CD40 activation in human pancreatic islets and ductal cells. Diabetologia 2008, 51:1853-1861.
• [25]Tzanakakis GN, Agarwal KC, Vezeridis MP: Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233. Canc 1993, 71:2466-2471.
• [26]Bergmann S, Pandolfi PP: Giving blood: a new role for CD40 in tumorigenesis. J Exp Med 2006, 203:2409-2412.
• [27]Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC: Standards for reporting of diagnostic accuracy: towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin Chem 2003, 49:1-6.
• [28]McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072.
• [29]Hock BD, McKenzie JL, Patton NW, Drayson M, Taylor K, Wakeman C, Kantarjian H, Giles F, Albitar M: Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Canc 2006, 106:2148-2157.
• [30]Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ: Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Canc Res 2001, 7:691-703.
• [31]Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M: Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol 2003, 23:1697-1702.
• [32]Amirkhosravi A, Amaya M, Desai H, Francis JL: Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis 2002, 13:505-512.
• [33]Tai YT, Podar K, Gupta D, Lin B, Young G, Akiyama M, Anderson KC: CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002, 99:1419-1427.
• [34]Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, Tiboni F, Musiani P, Granger DN, Colombo MP: Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 2006, 203:2441-2450.